Also, targeting each of HAT1, PVT1, miR-619-5p, and EZH2 individually or in combination may enhance the cancer cells’ resistance to gemcitabine and increase the effects of chemotherapy and prognosis in patients (31, 56, 57). This evidence concerns the gene HAT1 and cancer.